Aspen Pharmacare aims for Canada entry with Ozempic generic by third quarter

Core Viewpoint - Aspen Pharmacare is set to register its unbranded version of Novo Nordisk's diabetes drug Ozempic in Canada by the second or third quarter of this year, aiming to be among the first to offer generic competition following the expiration of Novo's patent on semaglutide in January [1]. Company Summary - Aspen Pharmacare's CEO, Stephen Saad, indicated that the company is receiving feedback from regulators and anticipates registration could occur between May and September [1]. - The company is positioning itself to capitalize on the generic market for Ozempic in Canada, which is expected to enhance its competitive standing in the pharmaceutical industry [1].